应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
NTHI NeOnc Technologies Holdings
未开盘 05-06 16:00:00 EDT
5.31
+0.32
+6.41%
盘后
5.31
+0.00
0.00%
19:20 EDT
最高
5.38
最低
4.70
成交量
8.65万
今开
5.01
昨收
4.99
日振幅
13.63%
总市值
1.34亿
流通市值
5,339万
总股本
2,519万
成交额
43.76万
换手率
0.86%
流通股本
1,005万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Neonc Technologies Holdings, Inc. 董事长兼CEO斥资约30万美元购入公司股票,并就2025年财务业绩提供说明
美股速递 · 04-14
Neonc Technologies Holdings, Inc. 董事长兼CEO斥资约30万美元购入公司股票,并就2025年财务业绩提供说明
Neonc Technologies Holdings公司——Neo100二期a阶段试验完成患者招募,中期数据预计2026年8月公布
美股速递 · 04-01
Neonc Technologies Holdings公司——Neo100二期a阶段试验完成患者招募,中期数据预计2026年8月公布
Neonc Technologies公布口服Neo212一期剂量递增试验结果:确定二期推荐剂量 管理层将于美东时间上午9点召开KOL电话会议
美股速递 · 03-04
Neonc Technologies公布口服Neo212一期剂量递增试验结果:确定二期推荐剂量 管理层将于美东时间上午9点召开KOL电话会议
Neonc Technologies获Cinctive Capital Management领投1000万美元战略PIPE投资
美股速递 · 01-30
Neonc Technologies获Cinctive Capital Management领投1000万美元战略PIPE投资
NeOnc Technologies Holdings:向市场提交出售最多111,732股普通股的招股说明书
美股速递 · 2025-12-24
NeOnc Technologies Holdings:向市场提交出售最多111,732股普通股的招股说明书
NeOnc Technologies Holdings - 持续使用Neo100鼻用剂量未显示显著毒性
美股速递 · 2025-11-12
NeOnc Technologies Holdings - 持续使用Neo100鼻用剂量未显示显著毒性
NeOnc Technologies Holdings 达到44%的六个月无进展生存率,超越基准
美股速递 · 2025-11-12
NeOnc Technologies Holdings 达到44%的六个月无进展生存率,超越基准
加载更多
公司概况
公司名称:
NeOnc Technologies Holdings
所属市场:
NASDAQ
上市日期:
--
主营业务:
Neonc Technologies Holdings, Inc.于2023年1月5日注册成立,为特拉华州公司。作为一家临床阶段的生物制药公司,该公司一直专注于建立颅内恶性肿瘤的治疗方法,即位于大脑的侵袭性癌症。这些癌症类型包括原发性脑癌,如胶质母细胞瘤,和继发性脑癌,它们是通过全身其他癌症的转移扩散而来的,如黑色素瘤或乳腺癌和肺癌。大脑局限性恶性肿瘤特别难以治疗,因为血脑屏障阻止了大多数药物治疗剂有效进入大脑。因此,这些患者面临着预后不良和平均预期寿命缩短的问题。NeOnc正在开发新的药物递送方法,用于与新的候选药物联合使用。
发行价格:
--
{"stockData":{"symbol":"NTHI","market":"US","secType":"STK","nameCN":"NeOnc Technologies Holdings","latestPrice":5.31,"timestamp":1778097600000,"preClose":4.99,"halted":0,"volume":86533,"hourTrading":{"tag":"盘后","latestPrice":5.31,"preClose":5.31,"latestTime":"19:20 EDT","volume":235,"amount":1246.92,"timestamp":1778109643290,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.06412825651302592,"floatShares":10054100,"shares":25189300,"eps":-3.203615,"marketStatus":"未开盘","change":0.32,"latestTime":"05-06 16:00:00 EDT","open":5.01,"high":5.38,"low":4.7,"amount":437583.449187,"amplitude":0.136273,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.203615,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1778140800000},"marketStatusCode":0,"adr":0,"listingDate":1711512000000,"exchange":"NASDAQ","adjPreClose":4.99,"preHourTrading":{"tag":"盘前","latestPrice":5.04,"preClose":4.99,"latestTime":"09:29 EDT","volume":1284,"amount":6451.5098736,"timestamp":1778074141034,"change":0.05,"changeRate":0.01002,"amplitude":0.032064},"postHourTrading":{"tag":"盘后","latestPrice":5.31,"preClose":5.31,"latestTime":"19:20 EDT","volume":235,"amount":1246.92,"timestamp":1778109643290,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.542653},"requestUrl":"/m/hq/s/NTHI","defaultTab":"news","newsList":[{"id":"1188238458","title":"Neonc Technologies Holdings, Inc. 董事长兼CEO斥资约30万美元购入公司股票,并就2025年财务业绩提供说明","url":"https://stock-news.laohu8.com/highlight/detail?id=1188238458","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188238458?lang=zh_cn&edition=full","pubTime":"2026-04-14 21:02","pubTimestamp":1776171739,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings, Inc. (以下简称\"公司\")今日宣布,其董事长兼首席执行官近期已斥资约30万美元,在公开市场购入了公司股票(股票代码:NTHI)。此次内部人士的增持行为,彰显了公司核心管理层对未来发展的坚定信心。\n与此同时,公司管理层也针对近期公布的2025年财务业绩提供了进一步的背景说明和解读,旨在帮助投资者更全面地理解公司的财务状况与战略方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155729765","title":"Neonc Technologies Holdings公司——Neo100二期a阶段试验完成患者招募,中期数据预计2026年8月公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1155729765","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155729765?lang=zh_cn&edition=full","pubTime":"2026-04-01 21:05","pubTimestamp":1775048712,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings公司宣布,其创新药物Neo100的二期a阶段临床试验已完成全部患者入组工作。该项研究的重要里程碑为后续数据评估奠定基础,中期研究结果预计将于2026年8月正式披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115650367","title":"Neonc Technologies公布口服Neo212一期剂量递增试验结果:确定二期推荐剂量 管理层将于美东时间上午9点召开KOL电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1115650367","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115650367?lang=zh_cn&edition=full","pubTime":"2026-03-04 21:03","pubTimestamp":1772629426,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings宣布口服抗癌药物Neo212的一期临床试验剂量递增阶段数据。研究明确了药物的安全剂量范围与毒性特征,并成功确定了二期临床试验推荐使用剂量。\n公司管理层将于美东时间今日上午9点举办关键意见领袖电话会议,深入解读临床数据及后续开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191348497","title":"Neonc Technologies获Cinctive Capital Management领投1000万美元战略PIPE投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1191348497","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191348497?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:01","pubTimestamp":1769781715,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings成功获得由Cinctive Capital Management主导的战略性PIPE(私募股权投资公开股)融资,其中Cinctive Capital Management单独注资1000万美元。此次投资将强化Neonc Technologies在医疗科技领域的研发能力与市场扩张步伐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162930745","title":"NeOnc Technologies Holdings:向市场提交出售最多111,732股普通股的招股说明书","url":"https://stock-news.laohu8.com/highlight/detail?id=1162930745","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162930745?lang=zh_cn&edition=full","pubTime":"2025-12-24 06:10","pubTimestamp":1766527827,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings:向市场提交出售最多111,732股普通股的招股说明书","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174332497","title":"NeOnc Technologies Holdings - 持续使用Neo100鼻用剂量未显示显著毒性","url":"https://stock-news.laohu8.com/highlight/detail?id=1174332497","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174332497?lang=zh_cn&edition=full","pubTime":"2025-11-12 21:10","pubTimestamp":1762953033,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings - 持续使用Neo100鼻用剂量未显示显著毒性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132787745","title":"NeOnc Technologies Holdings 达到44%的六个月无进展生存率,超越基准","url":"https://stock-news.laohu8.com/highlight/detail?id=1132787745","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132787745?lang=zh_cn&edition=full","pubTime":"2025-11-12 21:10","pubTimestamp":1762953014,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings 达到44%的六个月无进展生存率,超越基准","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neonc.com","stockEarnings":[{"period":"1week","weight":0.2349},{"period":"1month","weight":-0.0749},{"period":"3month","weight":-0.4253},{"period":"6month","weight":-0.4753},{"period":"1year","weight":0.1518},{"period":"ytd","weight":-0.3579}],"compareEarnings":[{"period":"1week","weight":0.0313},{"period":"1month","weight":0.1137},{"period":"3month","weight":0.083},{"period":"6month","weight":0.0937},{"period":"1year","weight":0.3132},{"period":"ytd","weight":0.0761}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neonc Technologies Holdings, Inc.于2023年1月5日注册成立,为特拉华州公司。作为一家临床阶段的生物制药公司,该公司一直专注于建立颅内恶性肿瘤的治疗方法,即位于大脑的侵袭性癌症。这些癌症类型包括原发性脑癌,如胶质母细胞瘤,和继发性脑癌,它们是通过全身其他癌症的转移扩散而来的,如黑色素瘤或乳腺癌和肺癌。大脑局限性恶性肿瘤特别难以治疗,因为血脑屏障阻止了大多数药物治疗剂有效进入大脑。因此,这些患者面临着预后不良和平均预期寿命缩短的问题。NeOnc正在开发新的药物递送方法,用于与新的候选药物联合使用。","exchange":"NASDAQ","name":"NeOnc Technologies Holdings","nameEN":"NeOnc Technologies Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NeOnc Technologies Holdings(NTHI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供NeOnc Technologies Holdings(NTHI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"NeOnc Technologies Holdings,NTHI,NeOnc Technologies Holdings股票,NeOnc Technologies Holdings股票老虎,NeOnc Technologies Holdings股票老虎国际,NeOnc Technologies Holdings行情,NeOnc Technologies Holdings股票行情,NeOnc Technologies Holdings股价,NeOnc Technologies Holdings股市,NeOnc Technologies Holdings股票价格,NeOnc Technologies Holdings股票交易,NeOnc Technologies Holdings股票购买,NeOnc Technologies Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NeOnc Technologies Holdings(NTHI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供NeOnc Technologies Holdings(NTHI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}